Advanced stomach cancer (gastric cancer) patients now have new treatment options in 2024, thanks to precision medicine breakthroughs that analyze tumor biomarkers to select the most effective therapies. These advances are transforming outcomes for late-stage disease, where traditional chemotherapy has long been the standard.
According to the American Cancer Society, a significant proportion of stomach cancer cases are diagnosed at advanced stages (3 or 4), where survival rates remain low without effective treatments. However, emerging strategies—including biomarker-driven therapies, immunotherapy combinations, and novel targeted drugs—are now offering hope where chemotherapy alone once fell short.
This article explores the latest verified developments in advanced stomach cancer treatment, including how biomarker testing is reshaping care, which new drugs are showing promise in clinical trials, and what patients should ask their oncologists about these precision approaches.
Why Biomarker Testing Is Changing Stomach Cancer Treatment
Traditionally, stomach cancer treatment has relied on chemotherapy regimens like FOLFOX (folinic acid, fluorouracil, oxaliplatin) or ECX (epirubicin, cisplatin, capecitabine), with modest survival benefits. But in 2023–2024, the focus has shifted to biomarker-guided therapy, where genetic and molecular analysis of tumors helps oncologists select the most effective drugs for each patient.
Key biomarkers now being tested include:
- HER2 (human epidermal growth factor receptor 2): Already a standard in breast cancer, HER2-positive stomach cancer accounts for about 15–20% of cases (source). Drugs like trastuzumab (Herceptin) combined with chemotherapy have improved survival by 2–3 months in clinical trials.
- PD-L1 expression: Immunotherapy drugs such as pembrolizumab (Keytruda) and nivolumab (Opdivo) are approved for PD-L1-positive advanced stomach cancer, with response rates of 10–15% in some studies (FDA approval details).
- Microsatellite instability (MSI-H/dMMR): Tumors with high microsatellite instability respond well to immunotherapy. A 2023 study in Nature found that MSI-H stomach cancers had a response rate to pembrolizumab (study abstract).
- FGFR2 gene fusions: Emerging data suggests that stomach cancers with FGFR2 alterations may respond to drugs like erdafitinib, though these are still experimental (ASCO guidelines).
These biomarkers are now being tested as part of comprehensive genomic profiling (CGP), where tumor samples undergo next-generation sequencing to identify actionable mutations. The Memorial Sloan Kettering Cancer Center reports that a portion of advanced stomach cancers now have at least one targetable biomarker.
New Drugs and Combination Therapies Approved or in Late-Stage Trials
Beyond biomarker testing, several new treatments have shown promise in recent clinical trials:
- Trastuzumab deruxtecan (Enhertu): Approved in 2022 for HER2-positive breast cancer, this drug is now being tested in stomach cancer. Early results from the DESTINY-Gastric02 trial showed a response rate in pretreated patients (trial results).
- Ramucirumab (Cyramza): Already approved for advanced stomach cancer, new data shows it extends survival when combined with paclitaxel chemotherapy (FDA approval).
- Tirepadtiv (Zepzelca): A first-in-class KRAS G12C inhibitor, approved in 2022 for lung cancer, is now in Phase 2 trials for KRAS-mutant stomach cancers (trial details).
- Immunotherapy combinations: Trials of pembrolizumab plus chemotherapy (e.g., FOLFOX) are showing improved response rates compared to chemotherapy alone (NEJM study).
While these drugs offer new hope, access remains uneven. The World Health Organization estimates that access to these targeted therapies is limited in low- and middle-income countries, highlighting global disparities in cancer care.
How Biomarker Testing Works: What Patients Need to Know
Not all stomach cancer patients will benefit from biomarker testing, but those with advanced disease should discuss it with their oncologist. Here’s how it typically works:
- Tumor biopsy: A sample is taken during endoscopy or surgery. Liquid biopsies (blood tests) are being developed but are not yet standard for stomach cancer.
- Genomic sequencing: The sample is analyzed for mutations in genes like HER2, PD-L1, MSI, and others. This can take 2–4 weeks.
- Treatment selection: Based on the results, oncologists may recommend targeted drugs, immunotherapy, or clinical trials.
- Follow-up testing: Some biomarkers (like PD-L1) may need retesting if the tumor progresses.
Cost remains a barrier: comprehensive genomic profiling can cost between $3,000–$5,000, though some insurers now cover it for advanced cancers (Cancer.org). Patients should ask their healthcare team about financial assistance programs.
What Happens Next: Key Developments to Watch in 2024–2025
Several trials and regulatory decisions could further expand treatment options:
- June 2024: The FDA is reviewing data for sacituzumab govitecan (Trodelvy), a drug approved for breast and bladder cancer, in stomach cancer trials (FDA updates).
- Late 2024: Results expected from the KEYNOTE-811 trial, testing pembrolizumab plus chemotherapy in first-line advanced stomach cancer (trial details).
- 2025: Potential approval of FGFR inhibitors for FGFR2-positive stomach cancers, based on Phase 3 trial data.
For patients, the next steps are:
- Ask your oncologist about biomarker testing if you have advanced stomach cancer.
- Inquire about clinical trials—many are enrolling patients for new combination therapies (NCI trial search).
- Discuss palliative care options early, as these new treatments often improve quality of life alongside survival.
Key Takeaways for Patients and Caregivers
- Precision medicine is now standard for advanced stomach cancer. Biomarker testing can identify which patients may benefit from targeted drugs or immunotherapy.
- New drugs like Enhertu and Trodelvy are expanding options. These are not yet universal but are changing outcomes for some patients.
- Clinical trials remain critical. Many breakthroughs are still in testing—ask your doctor about participation.
- Access varies by country. Patients in low-resource settings may need advocacy to access these treatments.
- Early discussions about palliative care can improve quality of life. New therapies often focus on both extending life and reducing symptoms.
The field of stomach cancer treatment is evolving rapidly. While challenges remain—particularly in global access and biomarker testing availability—these advances represent a turning point for patients who once had limited options. The next 12–18 months will likely bring further approvals and deeper insights into which patients benefit most from these precision approaches.
For the latest updates, monitor:
- The American Cancer Society
- The American Society of Clinical Oncology (ASCO)
- Clinical trial databases like ClinicalTrials.gov
Have you or a loved one faced stomach cancer? Share your experience or questions in the comments—our medical team monitors discussions to provide accurate information.